Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Retained Earnings (2016 - 2026)

United Therapeutics' Retained Earnings history spans 17 years, with the latest figure at $8.6 billion for Q4 2025.

  • On a quarterly basis, Retained Earnings rose 18.48% to $8.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $8.6 billion, a 18.48% increase, with the full-year FY2025 number at $8.6 billion, up 18.48% from a year prior.
  • Retained Earnings hit $8.6 billion in Q4 2025 for United Therapeutics, up from $100000.0 in the prior quarter.
  • Over the last five years, Retained Earnings for UTHR hit a ceiling of $8.6 billion in Q4 2025 and a floor of -$65.5 million in Q2 2022.
  • Historically, Retained Earnings has averaged $4.0 billion across 5 years, with a median of $4.4 billion in 2021.
  • Biggest five-year swings in Retained Earnings: skyrocketed 192485.71% in 2021 and later crashed 101.62% in 2022.
  • Tracing UTHR's Retained Earnings over 5 years: stood at $4.3 billion in 2021, then rose by 16.86% to $5.0 billion in 2022, then rose by 19.53% to $6.0 billion in 2023, then grew by 19.83% to $7.2 billion in 2024, then increased by 18.48% to $8.6 billion in 2025.
  • Business Quant data shows Retained Earnings for UTHR at $8.6 billion in Q4 2025, $100000.0 in Q3 2025, and $7.9 billion in Q2 2025.